Table 1.
Regimen for CNS+ BL patients at Beijing Children's Hospital.
| Parameters | Dosage (mg/m2) | Time (days) |
| COP | ||
| CTX | 300 | 1 |
| VCR | 2 | 1 |
| Pred | 60 | 1–7 |
| TIT | MTX+Dex+Ara-C | 1, 3, 5 |
| COPADM1 | ||
| VCR | 2 | 1 |
| HD-MTX | 5000 | 1,4 h |
| CF | 15 | 2–4 (MTX 24 h) |
| DNR | 30 | 2–3, 6 h |
| CTX | 500 | 2, 3, 4 (Q 12 h) |
| Pred | 60 | 1–5 |
| TIT | MTX+Dex+Ara-C | 2, 4, 6 |
| COPADM2 (same as COPADM1, only except) | ||
| HD-MTX | 8000 | 1, 4 h |
| CTX | 1000 | 2, 3, 4 (Q 12 h) |
| CYVE1/CYVE2 | ||
| Ara-C | 50 | 1–5 (8 pm–8 am) |
| HD- Ara-C | 3000 | 2–5 (8 am–11 pm) |
| VP16 | 100 | 2–5 (2 pm–4 pm) |
| HD-MTX | 8000 | Day 18–25 after CYVE1 only |
| TIT | MTX+Dex+Ara-C | 24 h after HD-MTX |
| M1 (same as COPADM2, only except) | ||
| HD-MTX | 8000 | 1 |
| CTX | 1000 | 2, 3 (Q12 h) |
| ADR | 60 | 2, 3, 6 h |
| TIT | MTX+Dex+Ara-C | 2 |
| M3 | ||
| VCR | 2 | 1 |
| ADR | 30 | 1, 2 |
| CTX | 500 | 1, 2 |
| Pred | 60 | 1–5 |
| M2 and M4 | ||
| VP16 | 150 | 1–3 |
| Ara-C | 100 | 1–5 |
The data are presented as the standard dosage of each drug in every course and the usage of duration. ADR: Doxorubicin; Ara-C: Cytarabine; BL: Burkitt's lymphoma; CF: Calcium folinate; CNS: Central nervous system; CNS+: Central nervous system-positive; COP: CTX + VCR + Pred; COPADM: CTX + VCR + Pred + VCR + DNR + MTX; CTX: Cyclophosphamide; CYVE: Ara-C + VP16; Dex: Dexamethasone; DNR: Daunorubicin; HD-MTX: High-dose methotrexate; M: Maintenance; Pred: Prednisone; TIT: Triple intrathecal; VCR: Vincristine; VP16: Etoposide.